Phase Ib Dose Finding Study of Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765) Plus Lenalidomide / Rituximab in Relapsed or Refractory Mantle Cell Lymphoma (MCL)
Latest Information Update: 03 Feb 2025
At a glance
- Drugs Ibrutinib (Primary) ; Lenalidomide (Primary) ; Rituximab (Primary)
- Indications Mantle-cell lymphoma
- Focus Adverse reactions
Most Recent Events
- 30 Jan 2025 Planned End Date changed from 1 Dec 2024 to 1 Oct 2025.
- 16 Feb 2024 Planned End Date changed from 1 Jan 2024 to 1 Dec 2024.
- 02 May 2023 Planned End Date changed from 1 Dec 2022 to 1 Jan 2024.